Monte Rosa Therapeutics (GLUE) Other Non-Current Assets: 2023-2025
Historic Other Non-Current Assets for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $5.0 million.
- Monte Rosa Therapeutics' Other Non-Current Assets rose 0.86% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 0.86%. This contributed to the annual value of $4.9 million for FY2024, which is 6.18% up from last year.
- Per Monte Rosa Therapeutics' latest filing, its Other Non-Current Assets stood at $5.0 million for Q3 2025, which was down 0.00% from $5.0 million recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' Other Non-Current Assets peaked at $5.3 million during Q1 2023, and registered a low of $4.5 million during Q3 2023.
- Over the past 3 years, Monte Rosa Therapeutics' median Other Non-Current Assets value was $4.9 million (recorded in 2024), while the average stood at $4.8 million.
- Within the past 5 years, the most significant YoY rise in Monte Rosa Therapeutics' Other Non-Current Assets was 8.54% (2024), while the steepest drop was 7.92% (2024).
- Monte Rosa Therapeutics' Other Non-Current Assets (Quarterly) stood at $4.6 million in 2023, then grew by 6.18% to $4.9 million in 2024, then climbed by 0.86% to $5.0 million in 2025.
- Its Other Non-Current Assets stands at $5.0 million for Q3 2025, versus $5.0 million for Q2 2025 and $4.9 million for Q1 2025.